Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD
2.
According to a study, white Americans are overdiagnosing melanoma at an alarming rate.
3.
Home Screening Appeals to Women Facing Healthcare Barriers
4.
Tumor characteristics found to differ for melanomas in children, teens and young adults
5.
Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients
1.
Progressive Models in Hematology for Healthcare Excellence
2.
Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications
3.
Liquid Biopsy in SCLC: cfDNA Profiling for Diagnosis and Treatment Monitoring
4.
Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights
5.
CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge